Skip to content
drillr.ai

MRNA

Moderna, Inc.

NASDAQ · USHealthcareBiotechnology
$59.49-3.77%

Price as of Jul 20, 2026

MRNA news

Moderna, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

    CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets. "mRNA-

    ACCESSWIRE ·

  2. Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

    CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. * Webcast: https://investors.modernatx.com The archived webcast

    ACCESSWIRE ·

  3. Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine

    FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 9-0 that the benefits of mRNA-1010, Moderna's investigational seasonal influenza vaccine, outweigh its risks for the prevention of influenza disease in adults 50 through

    ACCESSWIRE ·

  4. Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome

    Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%([1]) The INTERCEPT-Lynch trial is part of a scientific collaboration between the University of Oxford and Moderna to advance a novel mRNA approach to cancer prevention OXFORD, UK AND CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / June 8, 2026 / The University of Oxford and Moderna, Inc. (NASDAQ:MRNA) today announced a Phase 1/2 study of mRNA-4194, Moderna's inve

    ACCESSWIRE ·

  5. Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

    Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / June 1, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus d

    ACCESSWIRE ·

  6. Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

    Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / May 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a publication in the New England Journal of Medicine (https://pr.report/lcfn) of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficac

    ACCESSWIRE ·

  7. Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

    Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 billion non-recurring litigation settlement charge Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026, excluding the non-recurring litigation settlement charge Advanced infectious disease portfolio with key regulatory milestones in the EU, includin

    ACCESSWIRE ·

  8. Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate

    Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of the Company's investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, the Coalition f

    ACCESSWIRE ·

  9. Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19

    mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized product mCOMBRIAX will be made available in the European Union, subject to national regulatory and access procedures CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX(®) (mRNA-1083), the Company's mRNA

    ACCESSWIRE ·

  10. Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

    The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS>1%) CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 17, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (

    ACCESSWIRE ·

  11. Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

    CAMBRIDGE, MA / ACCESS Newswire (https://www.accessnewswire.com/) / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA(®) (mRNA-1345), its mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-

    ACCESSWIRE ·